6533b828fe1ef96bd1288f22
RESEARCH PRODUCT
Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group.
Pasquale ComellaSergio PalmeriLuigi MaiorinoVito LorussoCarlo PutzuS. MancarellaEttore GrecoLuca FrancoMario RoselliGiacomo VessiaClaudia SandomenicoRossana CasarettiBruno MassiddaSilvana LeoMichele Cannonesubject
OncologyMaleCancer ResearchOrganoplatinum CompoundsAntimetabolitesSettore MED/06 - Oncologia Medicamedicine.medical_treatmentAntidotesLeucovorinKaplan-Meier EstimateToxicologyPhytogenicAntineoplastic Combined Chemotherapy Protocols80 and overMedicinePharmacology (medical)Stomach cancerTomographyAged 80 and overMiddle AgedAntineoplasticMagnetic Resonance ImagingX-Ray ComputedOxaliplatinOncologyFluorouracilFemaleFluorouracilmedicine.drugAdultmedicine.medical_specialtyAntimetabolites AntineoplasticAntineoplastic AgentsNeutropeniaAdenocarcinomaIrinotecanFolinic acidStomach NeoplasmsTomography X-Ray Computed; Male; Aged 80 and over; Antimetabolites Antineoplastic; Middle Aged; Kaplan-Meier Estimate; Camptothecin; Survival Analysis; Female; Fluorouracil; Adenocarcinoma; Leucovorin; Humans; Organoplatinum Compounds; Antineoplastic Agents; Stomach Neoplasms; Magnetic Resonance Imaging; Antidotes; Blood Cell Count; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Agents Phytogenic; Aged; AdultInternal medicineHumansAgedPharmacologyChemotherapybusiness.industryGastric cancerFluorouracilIrinotecan OxaliplatinTriplet regimenmedicine.diseaseAntineoplastic Agents PhytogenicSurvival Analysisdigestive system diseasesOxaliplatinBlood Cell CountIrinotecanCamptothecinbusinessTomography X-Ray ComputedFebrile neutropeniadescription
Purpose: This phase II trial assessed the tolerability and efficacy of a triplet of oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer. Methods: Patients with unresectable or metastatic gastric cancer, unexposed to palliative chemotherapy, received oxaliplatin 85 mg/m 2 iv and irinotecan 150 mg/m2 iv on day 1, 6S-folinic acid 250 mg/m2 iv and fluorouracil 750 mg/m2 iv on day 2, every 2 weeks. Response rate (RR) was assessed after a minimum of four cycles, and treatment continued up to 12 cycles. Results: Sixty-three patients were treated, with a median of eight (range 1-12) cycles/patient. Two complete and 19 partial responses were registered (RR 33% [95% CI, 22-46%]). Median progression-free survival was 7.5 (95% CI, 5.6-9.4) months, and median overall survival was 12.1 (95% CI, 10.8-13.4) months. Most common grade ≥3 toxicities were neutropenia (59%), febrile neutropenia (7%), vomiting (20%), and diarrhoea (10%). All-grade neurotoxicity affected 33% of patients. Conclusions: Oxaliplatin, irinotecan, and fluorouracil/folinic acid administered every 2 weeks are safe and active in advanced gastric cancer.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2009-10-01 | Cancer chemotherapy and pharmacology |